The Australia story: Current status and future challenges for the clinical applications of psychedelics

Introduction

Nutt and colleagues place recent clinical progress with classical psychedelics and MDMA in the context of a large, unmet burden of mental illness and limited effectiveness of existing treatments. They note rapid advances in clinical trials over the past decade (with many agents reaching Phase II and some moving into Phase III), and describe basic pharmacology relevant to clinical action: psilocybin and related 5-HT2A agonists act on cortical layer 5 pyramidal neurons in a way that can disrupt ruminative activity in depression, while MDMA primarily releases serotonin and through 5-HT1A-related mechanisms attenuates fear responses relevant to PTSD. The paper also flags important regulatory milestones, in particular the Australian Therapeutic Goods Administration’s (TGA) decision to approve psilocybin for treatment-resistant depression and MDMA for PTSD to take effect on 1 July 2023, and notes that the article was written before the US FDA’s later rejection of MDMA in June 2024. This paper sets out to explain the background to the TGA decision, to describe how the Australian authorisation framework will work in practice, and to consider implications for other jurisdictions and for the development pathways of other psychedelic drugs. Rather than presenting new trial data, the authors undertake a narrative review and policy analysis of the regulatory process, stakeholder submissions, trial evidence cited by proponents and opponents, and practical delivery models that have been proposed for bringing these medicines into clinical use in Australia.